Senior Living : FDA Approved Extended Treatment for Alzheimer’s Dementia

Senior Living : FDA Approved Extended Treatment For Alzheimer’s Dementia
Senior face each day, families across the United States are struck with the diagnosis that a loved one suffers from …..

Senior face each day, families across the United States are struck with the diagnosis that a loved one suffers from Alzheimer’s dementia. For both men and women who suffer, this progressive disease marks the beginning of a long and complicated battle in the late stage of life, leaving many Alzheimer’s patients dependent upon family and loved ones for their care.

In an effort to remedy the complications associated with Alzheimer’s dementia, Ortho-McNeil Neurologics, Inc., has released an extended release FDA approved drug, Razadyne ER, to aide Alzheimer’s patients in regaining some control over the irregular pattern of loss of memory and provide, to some extent, a restoration to a somewhat normal, active and healthy life. For patients who suffer from a mild to moderate Alzheimer’s dementia, appropriate testing should be completed to confirm the diagnosis and rule out other complicating health factors. When confirmed as mild to moderate, age-related, Alzheimer’s dementia, Razadyne ER may provide the relief needed.

As a convenient extended release dosing formula, Razadyne ER, in the treatment of mild to moderate Alzheimer’s dementia, is provided in eight milligram, 16 milligram and 24 milligrams per day with most patients progressing to the 24 milligrams after beginning on eight milligrams for four weeks. As an extended release formula, in the treatment of mild to moderate Alzheimer’s dementia, patients are now afforded the relief needed in a once-per-day dosing that is rarely forgotten as would commonly occur in multiple daily dosing formulas.

Assisted Living Facilities
Family Questions: The First Thirty Days
Coping with the Transition
Emotional Issues: Introduction
I feel so relieved – and …..

As with most FDA approved drugs, the use of Razadyne ER, in the treatment of a mild to moderate Alzheimer’s dementia, may result in side effects. As a general rule, most side effects will dissipate as treatment progresses and maximum therapeutic benefit is attained. When using extended release Razadyne ER, side effects most commonly experienced by patients include nausea, vomiting, dizziness and even syncope. When using Razadyne ER, in the treatment of a mild to moderate Alzheimer’s dementia, consult the prescribing physician should these complications become more severe or do not dissipate through the course of treatment.

Contraindications, in the use of Razadyne ER, in the treatment of mild to moderate Alzheimer’s dementia, include those patients with co-morbid complications including kidney failure or renal complications, complications of the bladder, complications of the gastrointestinal tract, respiration, cardiovascular system and even complications of the nervous system.

Senior Living For Independent Living For Elderlyng For Elderlyng For Elderly
There are three basic ways to pay for long-term care in a nursing home: Medicare, Medicaid or private pay (out of …..

Comments are closed.